← Back to Home

Selectively Activating T Cells: Early Trial of Cancer Drug invikafusp Shows Signals of Tumor Shrinkage

At the optimal biologically active dose, 4 of 27 patients had an objective response. This dual-agonist therapy offers leads for research in refractory solid tumors, but the small trial cannot yet establish a survival benefit.

By SURL BioNews

When cancer becomes resistant to immunotherapy, a challenge in drug development is how to remobilize immune cells without allowing stimulation to become uncontrolled. The experimental drug invikafusp alfa aims to selectively activate certain T cells. Recently released early clinical results from START-001 showed tumor shrinkage in some patients with advanced solid tumors who had limited treatment options.

Results from this phase I/II trial, co-led by a cancer research team at Mass General Brigham and sponsored by Marengo Therapeutics, were published in Nature Medicine on October 23, 2026. The institution said the research was also presented at the 2026 European Society for Medical Oncology Congress. However, the data cutoff for the analysis in the paper was March 12, 2025; the recently released news should not be taken as an update on current enrollment.

Invikafusp is designed to act simultaneously on the T-cell receptor and interleukin-2 receptor on Vβ6/Vβ10 T cells, promoting their expansion. The study found increases in the corresponding cell populations in both blood and tumors, supporting the conclusion that the drug triggered its intended biological activity. However, clinical outcomes are still needed to establish a link between increased cell numbers and patient benefit.

The phase I dose-escalation portion enrolled 34 people, and the preliminary phase II portion enrolled another 18. Among the 27 people across both phases who received the optimal biologically active dose, the objective response rate was 14.8%, meaning that 4 people had tumor shrinkage meeting the assessment criteria. The institution also reported a disease control rate of 59.3%. This measure includes stable disease and cannot be interpreted entirely as tumor shrinkage.

Responses occurred in cases including microsatellite-stable colorectal cancer and PD-L1-negative non-small cell lung cancer. These results provide a rationale for further research but are not sufficient to draw conclusions about efficacy in individual cancer types. The study also showed that increasing the dose did not necessarily produce continued increases in biological activity. Taking safety, pharmacokinetics, and preliminary efficacy into account, the team selected 0.08 milligrams per kilogram as the recommended phase II dose.

Selective activation did not eliminate immune-related risks. The most common treatment-related adverse event was cytokine release syndrome, predominantly grade 1 or 2. Two people also experienced reversible dose-limiting toxicities at different doses. Although the trial did not reach the maximum tolerated dose and reported no treatment-related deaths, these findings do not establish the safety of long-term use.

The current results primarily support continued evaluation: the sample was small, included multiple cancer types, and lacked randomized controlled evidence for assessing relative efficacy. They cannot yet answer how long responses last, whether survival is extended, or which patients are most likely to benefit. The research received funding from Marengo Therapeutics and other organizations, and some authors were company employees or had financial relationships with the company. More complete efficacy and safety data will determine how far this strategy can advance.

References

  1. Mirage News
  2. Mass General Brigham
  3. PubMed